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Abstract
Background: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction
therapy, and approximately half of patients responding become unresponsive over time. Thus, identification
of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based
metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use
of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3)
to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors.
Methods: Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from 87 IBD
patients and 37 controls were analysed by 1H nuclear magnetic resonance (NMR) spectroscopy. Data were analysed
with principal components analysis and orthogonal projection to latent structures discriminant analysis using
SIMCA-P+ v12 and MATLAB.
Results: Metabolic profiles were significantly different between active ulcerative colitis and controls, active Crohn’s
disease and controls, and quiescent Crohn’s disease and controls. Metabolites holding differential power belonged
primarily to lipids and phospholipids with proatherogenic characteristics and metabolites in the pyruvate metabolism,
suggestive of an intense inflammation-driven energy demand. IBD patients not responding to IFX were identified as
a potentially distinct group based on their metabolic profile, although no applicable response biomarkers could be
singled out in the current setting.
Conclusion: 1H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With
its use, we provide unique insights into the metabolic changes taking place during induction treatment with IFX. Of
distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active
disease, which partially explains the increased risk of cardiovascular disease associated with IBD.
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Background
Ulcerative colitis (UC) [1] and Crohn’s disease (CD) [2] are
the two most prevailing entities of inflammatory bowel dis-
ease (IBD), characterised by chronic or recurrent episodes
of intestinal inflammation. Both UC and CD present as
multifactorial diseases believed to occur in genetically pre-
disposed individuals due to an abnormal immunologic re-
sponse to environmental and microbial components [3].
UC and CD share genetic and phenotypic characteristics;
however, they are distinct diseases requiring precise dif-
ferentiation to achieve optimal treatment regimens [4].
The diagnosis of IBD and the differentiation of UC and
CD are based on a time-consuming and costly multidis-
ciplinary approach (i.e. clinical history, endoscopy, radi-
ology, histology, microbiology and haematology) that is
hampered by the fact that approximately 10% of pa-
tients are left with the diagnosis of IBD unclassified [5].
Once a patient is diagnosed, selecting an individualised
treatment regimen becomes the next challenging step,
which is important because it involves costly biologic
agents such as tumour necrosis factor-α (TNF-α) inhib-
itors, i.e. infliximab (IFX) [6, 7].
IFX is effective in inducing and maintaining remission
of UC and luminal or fistulising CD. However, one-third
of IBD patients show no response at all to IFX induction
(i.e. primary non-responders) and up to half of patients
responding to IFX become unresponsive over time (i.e.
loss of response and thus withdrawal from treatment),
whereas the remaining patients achieve long-term remis-
sion with continued IFX therapy [8–11]. Consequently,
it is of great clinical and socioeconomic importance to
identify biomarkers of efficacy of IFX before therapy is
initiated. During ineffective IFX therapy, irremediable
disease progression may take place, subsequently leading
to severe outcomes. Further, the total cost of such un-
successful treatments is an enormous burden on public
health expenses.
In this respect, surprisingly few studies have focused
on identifying predictive response biomarkers [12–14].
However, with the advent and feasibility of proton
nuclear magnetic resonance (1H NMR) spectroscopy-
based metabolic profiling [15, 16] of serum in IBD
[17–21], metabonomics presents as an obvious tool
for differential diagnoses and identification of predict-
ive response biomarkers.
This study is a longitudinal cohort study of 1H NMR
spectroscopy-based metabolic profiling of serum from
IBD patients treated with IFX (1) to identify potential
diagnostic biomarkers that hold differential power with
respect to UC and CD patients and control subjects, (2)
to provide insight into the disordered metabolism during
active and quiescent IBD, and (3) to identify metabolic
changes during treatment with IFX in order to explore
markers of favourable outcomes.
Methods
Patient population
From May 2009 onward, blood samples were obtained
from IBD patients prior to IFX infusion as part of a local
drug monitoring program at the Department of Gastro-
enterology, Medical Section, Herlev Hospital, Denmark.
All eligible UC (n = 49) and CD (n = 38) patients were
naive to biologics, all had their diagnosis verified in ac-
cordance with well-established criteria [22, 23] and, at the
time of IFX infusion, they were all graded in accordance
with the Mayo score [24] (a score of 0–1: inactive UC, 2–
4: mild UC, 5–8: moderate UC, and 9–12: severe UC),
Harvey–Bradshaw (HB) score [25] (a score of 0–4: in-
active CD, 5–8: mild CD, 9–16: moderate CD, and > 16:
severe CD), and/or the perianal disease activity index [26]
(PDAI; a score from 0 to 20, with a higher score indicating
more severe disease). The healthy volunteer subjects (n =
37) were recruited locally among the staff at Herlev Hos-
pital and were free of any daily medications (see Tables 1
and 2 for clinical details). Exclusion criteria were age
above 80 or below 18 years; clinical evidence of any infec-
tions; recent (within 14 days) use of antibiotics, probiotics
or high-dose prednisolone (≥60 mg/day); pregnancy; severe
mental illness; and special food regimens such as a diet of
fermentable oligosaccharides, disaccharides, monosaccha-
rides and polyols, a diabetic diet or a gluten-free diet.
Classification of response to IFX
The outcome of IFX treatment was determined in
accordance with previous studies [27, 28]:
1. Remission (Rem) was defined as a favourable clinical
response to IFX induction (Mayo score < 2, HB
score < 5, PDAI score < 5), followed by a sustained
clinical remission at the initiation of maintenance
therapy, i.e. at week 14.
2. Response (Res) was defined as a beneficial clinical
response to IFX induction (reduced Mayo score, HB
score and/or PDAI score) but without complete
clinical remission (Mayo score ≥ 2, HB score ≥ 5,
PDAI score ≥ 5) at initiation of maintenance therapy,
i.e. at week 14 and despite subsequent dose
optimisation.
3. Non-response (NRes) was defined as no clinical
response to IFX induction therapy at weeks 2, 6 or 14.
Serum sample collection and preparation
Blood samples were collected during the induction treat-
ment with IFX and obtained as trough levels with sampling
30 min prior to an IFX infusion. Hence, samples were avail-
able from time-point 0 (before first infusion of IFX), 2 weeks
after the initial dose (before the second infusion), 6 weeks
after the initial dose (before the third infusion) and 14 weeks
after the initial dose (before continuing maintenance
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therapy, i.e. the fourth infusion). Patients with severe dis-
ease and no initial response to IFX treatment often never
received their third and fourth infusions of IFX. One sam-
ple was available from each control subject. In total, 359
samples were available for analysis from non-fasting pa-
tients and controls. Within 3 h of sampling, the serum was
collected after centrifugation (2500 × g for 5 min at ambient
temperature) and stored at −80 °C until analysis.
The serum was thawed and prepared for 1H NMR
spectroscopy by mixing 180 μL of serum with 60 μL of
400 mM phosphate buffer in an Eppendorf tube to
achieve a final concentration of 100 mM. A total of
180 μL from each of these mixed serum samples was
transferred into 3-mm sample tubes, briefly centrifuged
with a hand centrifuge to remove air bubbles, and subse-
quently placed in the high-throughput SampleJet robotic
system used for the 1H NMR experiment.
1H NMR spectroscopy
All 1H NMR experiments were performed at 288.1 K
using a Bruker 600-MHz spectrometer operating at
599.35 MHz for protons and equipped with an inverse
detection 5-mm cryogenic probe (BioSpin, Bruker,
Rheinstetten, Germany). For all samples, the 1H NMR
spectra were acquired using a Carr–Purcell–Meiboom–
Gill (CPMG) pulse sequence with an echo time of
160 ms. The 90-degree pulse length was approximately
8 μs, as calculated automatically for each sample. A total
of 128 scans were collected into 64,000 data points with
a spectral width of 14 ppm (8370 Hz; steady-state scans
= 8; acquisition time = 3.9 s). Metabolites were assigned
according to previously published data [29–31] and on-
line databases for metabonomics research such as Hu-
man Metabolome Database and Madison Metabolomics
Consortium Database.
Table 1 Clinical details
CD Total CD Rem CD Res CD NRes Control
Characteristics n = 49 n = 29 n = 11 n = 9 n = 37
Gender (male/female) 22/27 15/14 4/7 3/6 18/19
Age, years (mean, range) 40 (19–71) 39 (22–62) 42 (20–63) 42 (19–58) 42 (26–63)
Age at diagnosis (≤25/> 25 years) 26/23 15/14 7/4 4/5 –
Years with disease (≤10/> 10 years) 27/22 16/13 6/5 5/4 –
HB-score (mean, range) 10 (6–18)a 10 (6–18)c 11 (8–15) 11 (5–15)f –
PDAI (mean, range) 10 (2–12)b 9 (2–12)d 10 (9–12)e 7(6–9)g –
Extension (D, J, TI, IC, C) 1, 1, 17, 5, 35 0, 0, 9, 3, 23 0, 0, 6, 1, 7 1, 1, 2, 1, 5 –
Surgery (IR, IR + HC, HC, Co, IC + Co) 9, 1, 2, 9, 4 5, 0, 2, 5, 0 2, 1, 0, 2, 2 2, 0, 0, 2,2 –
Smoking/non-smoking 13/36 11/18 1/10 1/8 0/37
EIM (present/not present) 4/45 1/28 2/9 1/8 –
Steroids, n –
Independent/dependent/responder/unknown 7/20/8/14 4/12/3/10 2/4/2/3 1/4/3/1 –
Daily medication, n –
Systemic 5-aminosalicylic acid (1.6–3.2 g) 2 1 0 1 –
Topical 5-aminosalicylic acid (1 g) 0 0 0 0 –
Systemic glucocorticoids (75 mg)h 9 6 2 1 –
Topical glucocorticoids (100 mg) 1 1 0 0 –
Azathioprine (100–150 mg) 29 18 7 4 –
Methotrexate (25 mg/wk) 1 0 0 1 –
None 15 9 4 2 37
aSix patients had no luminal activity, only perianal fistulas
bIn all, fourteen patients had perianal fistulas
cFour patients had no luminal activity, only perianal fistulas
dIn all, seven patients had perianal fistulas
eThree patients had perianal fistulas
fOne patient had no luminal activity, only perianal fistulas
gIn all, three patients had perianal fistulas
hTappering regime
C colonic, Co colectomy, D duodenal, EIM extra-intestinal manifestations, HB Harvey–Bradshaw, HC hemicolectomy, IC ileocecal, IR ileocecal resection, J jejunal,
NRes non-responder, PDAI perianal disease activity index, Rem remission, Res responder, TI terminal ileum
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1H NMR spectroscopy procession
The free-induction decays for one-dimensional data
were zero-filled to 64,000 data points and multiplied by
an exponential function with a line-broadening factor of
1 Hz prior to Fourier transformation. All one-
dimensional 1H NMR spectra were manually corrected
for phase using TOPSPIN 3.1 (BioSpin, Bruker) and cor-
rected for baseline distortions, and referenced to the left
signal peak of α-glucose at 5.236 ppm using Mnova 8.1
(Mestrelab Research, Santiago de Compostela, Spain).
The 1H NMR spectral region 0.5–9.0 ppm was binned
with a width of 0.004 ppm (2 Hz) using the Mnova soft-
ware. Water regions (4.23–5.18 ppm) were removed to
avoid imperfect water saturation. The regions 1.43–1.50,
6.98–7.10, and 7.70–7.84 ppm, were aligned to avoid the
effect of chemical-shift drift. The 1H NMR spectra were
normalised to the total sum of the spectral integrals to
compensate for sample concentration differences.
Multivariate data analysis
The applied approach to multivariate data analysis has
previously been described in detail by Bjerrum et al. [32].
To visualise the general structure of each 1H NMR data-
set and to identify any abnormalities or outliers (based on
the principles of Hotelling’s T2) within the data, principal
components analyses were completed on mean-centred
data (SIMCA-P+ software v12.0, Umetrics, Umeå, Sweden).
Projection to latent structures discriminant analysis (PLS-
DA) and orthogonal projection to latent structures discrim-
inant analysis (O-PLS-DA) [33] were subsequently applied
to the 1H NMR spectral data scaled to unit variance to dis-
cover metabolic differences. O-PLS is an extension of the
partial least squares regression method, including an inte-
grated orthogonal signal-correction filter [34]. As described
by Cloarec et al. [35], analysis of the model is facilitated by
a back-scaled transformation of the loadings, with incorpo-
rated colour-coded correlation coefficients (MATLAB v7.1,
MathWorks, Natick, MA, USA) of the metabolites ac-
countable for the differentiation. Briefly, each back-scaled
loading is plotted as a function of the respective chemical
shift with a colour code that signifies the weights of the
discriminatory variables. A hot colour (e.g. red) signifies
metabolites that are markedly different between groups,
whereas a cool colour (e.g. blue) corresponds to no differ-
ences between groups.
To minimise the risk of overfitting and to validate the
PLS models, a sevenfold cross-validation procedure was
performed, involving iterative construction of models by
repeatedly leaving out one-seventh of the samples and
predicting them back into the model. This resulted in a
cross-validation parameter, Q2, indicating the predict-
ability of the model in relation to its statistical validity.
Furthermore, a cross-validation procedure, a permuta-
tion test, was completed for each model, wherein 200
Table 2 Clinical details
UC Total UC Rem UC Res UC NRes Control
Characteristics n = 38 n = 19 n = 9 n = 10 n = 37
Gender (male/female) 18/20 9/10 4/5 5/5 18/19
Age, years (mean, range) 39 (20–66) 41 (20–66) 38 (23–65) 37 (21–54) 42 (26–63)
Age at diagnosis (≤25/> 25 years) 15/23 5/14 4/5 6/4 –
Years with disease (≤10/> 10 years) 24/14 10/9 6/3 8/2 –
Mayo-score (mean, range) 7 (3–12) 6 (3–12) 8 (6–11) 7 (5–10) –
Extension (P, PS, LC, PC) 2/8/5/23 1/7/1/10 0/1/1/7 1/0/3/6 –
Surgery/no surgery 2/36 1/18 0/9 1/9 –
Smoking/non-smoking 2/36 1/18 1/8 0/10 0/37
EIM (present/not present) 0/38 0/19 0/9 0/10 –
Steroids, n –
Independent/dependent/responder 1/32/5 1/17/1 0/8/1 0/7/3 –
Daily medication, n –
Systemic 5-aminosalicylic acid (1.6–3.2 g) 29 13 7 9 –
Topical 5-aminosalicylic acid (1 g) 1 1 0 0 –
Systemic glucocorticoids (75 mg)a 18 9 4 5 –
Topical glucocorticoids (100 mg) 1 1 0 0 –
Azathioprine (100–150 mg) 25 14 5 5 –
None 0 0 0 0 37
aTappering regime
EIM extra-intestinal manifestations, LC left-sided colitis, NRes non-responder, P proctitis, PC pancolitis, PS proctosigmoiditis, Rem remission, Res responder
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models were constructed with the use of randomised
classification of the samples, and Q2 values were gener-
ated from these models and compared with the Q2
values of the real model. If the maximum value of Q2max
from the permutation test was smaller than the Q2 of
the real model, the model was regarded as a predictable
model. Similarly, R2 was used to evaluate possibly over-
fitted models. Finally, with the use of an analysis of vari-
ance of the cross-validated residuals (CV-ANOVA) [36]
test, a significance test was implemented to verify model
validity. Only if the permutation test and the CV-
ANOVA test were fulfilled at the same time were the
models considered valid. The actual predictive value of
each model was estimated with the use of receiver oper-
ating characteristics.
Correlation analyses between metabolites were per-
formed with the use of the respective resonance peaks
from the NMR spectra.
Results
Classification of clinical outcome
Patients with UC and CD were primarily classified into
three major groups stated above –Rem, Res and NRes.
These classifications were based on clinical scores (Mayo
or HB score and PDAI score) and concomitant biochem-
ical parameters (Figs. 1 and 2). Patients with CD who
went into remission had significant decreases in HB
and/or PDAI scores and C-reactive protein (CRP), and
an increase in haemoglobin. CD responders also had sig-
nificant decreases in HB score and CRP, but no signifi-
cant changes were seen in PDAI score or haemoglobin.
CD non-responders experienced no significant changes
at all (Fig. 1). Similarly, UC patients who went into re-
mission had a significant decrease in Mayo score and an
increase in haemoglobin and a trend toward decreased
CRP. UC responders had a significant decline in Mayo
score but without significant changes in haemoglobin or
CRP. UC non-responders had no changes at all (Fig. 2).
1H NMR spectra of serum
Typical 1H NMR spectra of serum obtained from pa-
tients with CD and UC as well as control subjects are
shown in Additional file 1: Figure S1. A range of en-
dogenous metabolites observed in the spectra is similar
to that of previously reported metabolites [17–21] and
consisted of different amino acids (e.g. valine, leucine,
isoleucine, alanine, arginine, lysine, glutamine, glutam-
ate, histidine, glycine, tyrosine and phenylalanine), short-
chain fatty acids (e.g. acetate and isobutyrate), energy
metabolism-related molecules (e.g. lactate, citrate and
creatine), and membrane metabolites, including glycero-
phosphocholine (GPC) and choline. Notably, a range of
lipids and lipoproteins (e.g. high-density lipoproteins
(HDLs), low-density lipoproteins (LDLs) and very low-
density lipoproteins (VLDL)) was also detected in the
NMR spectra.
A number of unknown metabolites (U1, U2 and U3)
was identified, but further characterisation was im-
possible in spite of correlation analysis with STOCSY
(statistical total correlation spectroscopy) and database
search.
Multivariate data analysis of 1H NMR spectra
Unsupervised analysis and outlier detection
Principal components analyses was initially applied to
the NMR spectra acquired from the serum using data
scaled to unit variance. Based on the principals of
Hotelling’s T2 (95% confidence limit), 16 samples were
identified as outliers and subsequently excluded. The
outliers were reviewed for any demographic abnormal-
ities, but none could be identified. Thus, the remaining
343 samples were accessible for subsequent supervised
multivariate data analysis (Additional file 2: Table S1).
Supervised analysis of phenotypes and identification of
metabolites
To classify the samples, PLS-DA models comparing con-
trol subjects with either UC or CD patients, UC versus
CD, treatment response types (i.e. Rem, Res and Nres),
and different disease states (i.e. weeks 0, 2, 6 and 14)
during the 14 weeks of treatment with IFX were gener-
ated, with CPMG NMR data as an X matrix and class
information as the Y variables [35]. To uncover the
metabolic changes holding differential power, the O-
PLS-DA strategy was subsequently applied to each
model. The O-PLS-DA models were constructed with
one PLS component and one orthogonal component.
The models were subsequently validated with the use of
a permutation test (for the PLS-DA models) and a CV-
ANOVA test (for the O-PLS-DA models).
As seen in Table 3, no significant models could be
created for CD(0) versus UC(0), indicating that no
differences in the metabolic profiles of active CD and
UC could be identified. Both CD(0) and UC(0), how-
ever, were easily distinguished from control subjects,
which was also true for CD Rem at all time points
during IFX treatment (Table 3). In contrast, UC Rem
became inseparable from control subjects during the
14 weeks of IFX treatment as patients went into re-
mission (Table 3). The corresponding score plots and
their back-scaled loading plots of the significant
models are shown in Fig. 3, where a clear separation
between each class is seen in the score plots. The
corresponding back-scaled loading plots reflect the
class differences of the NMR spectra and indicate
relatively increased or decreased intensities of metab-
olites. These back-scaled loading plots were converted
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into a comprehensive list of markedly up- and down-
regulated metabolites in Table 4. The actual predic-
tion performance estimates are presented in Table 3
as area under the curve (AUC) and correlate with the
results of the OPLS-DA models; all significant models
produce AUC values above 90. The AUCs are pre-
sented in Additional file 3: Figure S2.
Similar assessments were made between Res patients
and control subjects, between NRes patients and control
subjects, and between the different response types (i.e.
Rem, Res and NRes patients; Additional file 4: Table S2).
CD Res patients and UC Res patients could be distin-
guished from control subjects throughout the IFX induc-
tion period, whereas CD NRes patients and UC NRes
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Fig. 1 Markers of disease activity in patients with Crohn’s disease (CD). Changes in Harvey–Bradshaw (HB) scores, perianal disease activity index
(PDAI) and biochemical markers (C-reactive protein and haemoglobin levels) of disease activity during treatment of CD patients with infliximab
(IFX) measured at the time of IFX initiation (0) and at the fourth infusion (14). Rem remission, Res responder, NRes non-responder. * P < 0.05;
*** P < 0.001; **** P < 0.0001
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patients could not. Furthermore, the comparisons be-
tween the different response types resulted in insignifi-
cant models.
Next, the potential metabolic changes that take place
during the 14 weeks of IFX treatment were investigated
by comparing the consecutive time points within each
response type (i.e. Rem, Res and NRes in UC and CD
patients separately). Surprisingly, no significant models
could be identified (Additional file 5: Table S3; Add-
itional file 6: Table S4).
Finally, a correlation analysis was performed between
phenylalanine and tyrosine as phenylalanine is related
to the tyrosine metabolism and was found up-regulated
in IBD. This resulted in a significant positive correl-
ation (r = 0.447, P < 0.001, Additional file 7: Figure S3).
Supervised analysis of subphenotypes
A final analysis was performed on the different subpheno-
types where statistically possible; these were sex, age at
diagnosis (≤30, 31–40, ≥ 41 years), years with diagnosis
(≤10 years/> 10 years), Mayo and HB scores (mild, moder-
ate and severe), fistulising disease (no/yes), stenosis (no/
yes), extent of inflammation (left-sided colitis/pancolitis),
surgery (no/yes), smoking status (no/yes), extraintestinal
manifestations (present/not present) and glucocorticoids
(dependent/independent/responder). This was completed
by creating PLS-DA models for each patient category,
with NMR data as an X matrix and phenotype informa-
tion as the Y variables. None of the models, however,
turned out to be predictive (Additional file 5: Table S3 and
Additional file 6: Table S4).
Discussion
This 1H NMR spectroscopy-based metabonomics study
of serum samples demonstrates the differential power
and metabolic differences present between IBD patients
and control subjects and the changes taking place during
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Fig. 2 Markers of disease activity in patients with ulcerative colitis (UC). Changes in Mayo scores and biochemical markers (C-reactive protein and
haemoglobin levels) of disease activity during treatment of UC patients with infliximab (IFX) measured at the time of IFX initiation (0) and at the
fourth infusion (14). Rem remission, Res responder, NRes non-responder. ** P < 0.01; *** P < 0.001; **** P < 0.0001
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14 weeks of IFX treatment in different treatment re-
sponse types (i.e. Rem, Res or primary NRes).
Differentiation of CD and UC patients, control subjects
and IFX response types
The study confirms previously published studies [17–21]
and displays significant differential diagnostic power in
models comparing active UC patients versus control
subjects, active CD patients versus control subjects, and
remission CD patients versus control subjects but no
significant discrimination for active UC versus active CD
patients, active UC versus remission UC patients, active
CD versus remission CD patients, and remission UC pa-
tients versus control subjects (Table 3 and Additional file
5: Table S3 and Additional file 6: Table S4). No previous
studies have actually compared the active and quiescent
disease stages of CD and UC patients, although Dawis-
kiba et al. [17] did compare active IBD and remission
IBD patients and found significant metabolic profiles
that differentiated these two congregated cohorts. They
also compared remission IBD patients and control sub-
jects, but without any significant results. This, however,
contrasts with the findings of Williams et al. [20], who
were able to differentiate between remission CD patients
and control subjects, as in the present study, and remis-
sion UC patients and control subjects, in contrast to the
present study. The methodology and statistical proce-
dures in the study by Williams et al. [20] and those used
herein are comparable, and no obvious explanation has
been identified for the discrepancy in outcome.
The sustained metabolic changes at 14 weeks of IFX
treatment in the remission CD patients versus control
subjects might be an indication of the more profound
inflammation compared with the relatively superficial in-
flammation seen in UC patients; in Table 4, the number
of significant up- or down-regulated metabolites de-
creases as treatment proceeds from the initial IFX infu-
sion (CD Rem(0) vs. control) to the fourth infusion (CD
Table 3 Validation of PLS-DA and O-PLS-DA models
Model PLS-DA
permutation test n = 200
O-PLS-DA
CV-ANOVA
Area under the ROC curve
CD(0) vs. UC(0) Q2 = 0.095 Q2 = –0.182 0.44
× × P = 1
CD(0) vs. Control Q2 = 0.637, r = 0.32 Q2 = 0.7 0.96
✓ ✓P < 0.001
UC(0) vs. Control Q2 = 0.583, r = 0.32 Q2 = 0.383 0.94
✓ ✓P < 0.001
CD Rem(0) vs. Control Q2 = 0.63, r = 0.37 Q2 = 0.66 0.96
✓ ✓P < 0.001
CD Rem(2) vs. Control Q2 = 0.69, r = 0.37 Q2 = 0.66 0.95
✓ ✓P < 0.001
CD Rem(6) vs. Control Q2 = 0.52, r = 0.37 Q2 = 0.63 0.91
✓ ✓P < 0.001
CD Rem(14) vs. Control Q2 = 0.48, r = 0.40 Q2 = 0.62 0.90
✓ ✓P < 0.001
UC Rem(0) vs. Control Q2 = 0.56, r = 0.47 Q2 = 0.60 0.91
✓ ✓P < 0.001
UC Rem(2) vs. Control Q2 = 0.60, r = 0.48 Q2 = 0.60 0.94
✓ ✓P < 0.001
UC Rem(6) vs. Control Q2 = 0.25 Q2 = 0.52 0.71
× ✓P < 0.001
UC Rem(14) vs. Control Q2 = 0.17 Q2 = 0.37 0.64
× ✓P < 0.001
The models were only considered valid if the permutation test and the CV-ANOVA test (p < 0.05) were satisfied at the same time
(0), before 1st infusion of infliximab; (2), before 2nd infusion; (6), before 3rd infusion; (14), before 4th infusion
Q2, predictability of the model; r correlation coefficient
✓, valid model
X invalid model
CD Crohn’s disease, CV-ANOVA analysis of variance of the cross-validated residuals, O-PLS-DA orthogonal-projection to latent structure discriminant analysis, PLS-DA
projection to latent structure-discriminant analysis, Rem remission, ROC receiver operating characteristics, UC ulcerative colitis
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Rem(14) vs. control). In contrast, patients with UC have
fewer significant metabolic changes at the time of treat-
ment initiation (UC Rem(0) vs. control), and these
changes are already absent after 6 weeks of treatment.
This circumstance might also explain why the meta-
bolic profiles from the successive serum samples (i.e.
weeks 0, 2, 6 and 14) within each response type (i.e.
Rem, Res and NRes) did not show any significant dis-
crimination (Additional file 5: Table S3 and Additional
file 6: Table S4); the metabolic changes seen from week
0 through week 14 in patients with CD entering remis-
sion are simply too few (Table 4). Future studies need
to collect serum samples within an expanded time
frame, at least in CD patients. In contrast, patients with
UC entering remission have very few significantly
deregulated metabolites at the time of treatment
initiation (Table 4, UC Rem(0) vs. control), and the
subsequent metabolic changes may consequently be
insufficient to create significant discrimination between
successive serum samples.
As could be expected, the metabolic profiles of CD
Res and UC Res patients stayed significantly different
from that of control subjects (Additional file 4: Table S2)
throughout the induction period. Surprisingly, this was
not the case for CD NRes and UC NRes patients. The
obvious explanation is the relatively low number of sam-
ples in these groups (n = 9 and 10, respectively), but it
might also be explained by an entirely different meta-
bolic profile in the serum of patients who are primary
non-responders to IFX. However, comparing the differ-
ent response types (i.e. Rem, Res and NRes) did not pro-
duce any significant discrimination. Thus, in order to
answer this question, lager cohorts are needed in future
studies. Furthermore, the lack of discriminant power
might also be explained by the poor correlation in gen-
eral between clinical disease activity indices and the
Fig. 3 O-PLS-DA score plots and loading plots. O-PLS-DA score plots and corresponding coefficient-coded loading plots obtained from metabolic
profiles of 1H NMR spectra of the serum samples. The score plots display the first PLS component and one orthogonal component for each model. A
two-way separation of the samples is demonstrated in all plots. The corresponding back-scaled loading plots reflect the class differences in the NMR
spectra. Upright peaks indicate a relatively increased intensity of metabolites, and downright peaks a decreased intensity of metabolites. The colours
shown on the plot are associated with the significance of metabolites in separating the samples; red indicating significance at a level of P < 0.05. (0),
before first infusion of infliximab; (2), before second infusion; (6), before third infusion; (14), before fourth infusion. Glc glucose, Gln glutamine, GPC
glycerophosphocholine, Gly glycine, HDL high-density lipoproteins, His histidine, Lac lactate, NAG N-acetyl glycoprotein, Phe phenylalanine, U1, U2, U3
unknown metabolite, Val valine, VLDL very-low density lipoproteins, CD Crohn’s disease, UC ulcerative colitis, Rem remission
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actual burden of disease, although we did incorporate
biochemical parameters to substantiate the clinical
scores.
Metabolic profiles of IFX-treated IBD patients
An abnormal lipid metabolism was identified in both
CD and UC patients compared with control subjects.
LDL data could not be separated from the broad lipo-
protein NMR peak, but the identified low levels of HDL
and high levels of VLDL seem to be the consequence of
malabsorption, increased transit times and the inflam-
matory environment (e.g. TNF-α, interleukin-1 and -6).
TNF-α in particular has been shown to increase the re-
lease of free fatty acids from adipocytes, stimulate the
production of triglycerides in the liver, and inhibit lipo-
protein lipase and thereby the hydrolysis of triglycerides
in VLDL, leading to an increase in VLDL and a decrease
in HDL cholesterols [37]. This proatherogenic lipid pro-
file correlates with the increased incidence of cardiovas-
cular morbidity seen in IBD patients, particularly in
women and adolescents [38]. As seen in this study
(Table 4) and others [39, 40], treatment with IFX amelio-
rates this proatherogenic lipid profile in both UC and
CD patients. Thus, women and young adults with
chronically active disease or frequent flares might be
considered candidates for concomitant statin treatment
if other atherogenic risk factors are present. However,
the biobank from which the samples originated did not
contain patient data on quantitative lipid measurements
or other potential atherogenic risk factors except for sex,
age and smoking.
This study also demonstrated decreased levels of the
membrane metabolite GPC (Table 4). GPC is a deriva-
tive of the membrane metabolite choline and one of the
major forms of choline storage in the cytosol. The de-
creased levels of GPC may be a consequence of the
compromised integrity of the intestinal mucosal mem-
brane [15] with an inflammation-driven increased rate of
apoptosis and cellular turnover [41]. Interestingly, sus-
tained choline deprivation stimulates cell survival
through nuclear factor-kappa B activation, leading to
sustained inflammation and oncogenesis [42]. Further-
more, low levels of GPCs have been correlated with car-
diovascular disease [43], underlining the proatherogenic
nature of the inflammation.
In contrast to other studies [17, 19–21], low levels of
glucose and lactate were found in both UC and CD pa-
tients compared with control subjects, and these
changes persisted in CD patients achieving remission
after 14 weeks of IFX treatment (Table 4). The low level
Table 4 Significant up and down-regulated metabolites
(0), before 1st infusion of infliximab at week 0; (2), before 2nd infusion at week 2; (6), before 3rd infusion at week 6; (14), before 4th infusion at week 14
increased or ↓ decreased compared to controls (The coefficients from the OPLS-DA results, positive and negative signs, indicate positive and negative correlation
in the concentrations, respectively. The coefficient of 0.32–0.48 was used as the cut-off value in the different models (according to number of samples) for the
evaluation of significant differences (P < 0.05)
CD Crohn’s disease, GPC glycerophosphocholine, HDL high-density lipoprotein, NAG N-acetyl glycoprotein, Rem remission, U1, U2, U3 unknown metabolites, UC
ulcerative colitis, VLDL very-low density lipoprotein
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of glucose could be explained by impaired intestinal ab-
sorption due to the inflammation, which is more pro-
found in CD than UC. However, the concomitant low
level of lactate and high level of pyruvate indicate the
need for scavengers of reactive oxygen species [44] and
an inflammation-driven high energy demand with high
glycolytic activity and low lactate dehydrogenase activity
and hence accumulation of pyruvate but no production
of lactate [45].
Phenylalanine was persistently up-regulated and posi-
tively correlated with tyrosine in IBD patients even dur-
ing induction of remission, especially in patients with
CD (Table 4). This is in contrast to the other observed
amino acids (i.e. valine, glutamine, glycine and histidine;
Table 4). However, the pattern of increased aromatic
amino acids (e.g. phenylalanine and tyrosine) and a de-
crease in branched chain amino acids (e.g. valine) is well
known during catabolic conditions like sepsis and liver
failure [46, 47]. The inflammation-driven process causes
muscle proteolysis with a subsequent decrease in
branched chain amino acids due to muscle energy con-
sumption and an increase in aromatic amino acids due
to hepatic insufficiency with impairment of the hepatic
enzyme phenylalanine-4-hydroxylase [48].
Formate is an essential intermediary metabolite in vir-
tually all living organisms, but in this study, formate was
found in low levels in IBD patients (Table 4). This po-
tentially reflects the high demand of formate locally in
the inflamed intestines, where formate is tightly related
to folate metabolism [49]. A previous study [15] has in-
dicated an increased phospholipid metabolism (e.g. GPC
and choline) and glutathione synthesis (e.g. glutamine
and glycine) in inflamed colonic tissue from patients
with UC, and both of these processes are linked via the
methionine-homocysteine cycle, where formate and fol-
ate are essential and central elements [49].
N-Acetyl glycoprotein is a well-known acute-phase
protein, which is in accordance with the high levels
seen in this study (Table 4), but due to a long half-
life, it is not applicable as a useful clinical tool [50].
Finally, three unidentified metabolites were consist-
ently down-regulated in both active and inactive pa-
tients with IBD (Table 4).
Conclusions
1H NMR spectroscopy-based metabonomics on succes-
sive serum samples from patients with IBD has proven
to be a potentially powerful semi-invasive diagnostic tool
in flaring UC and CD, providing unique insights into the
metabolic changes taking place during induction treat-
ment with IFX. Thus, the identification of a reversible
proatherogenic lipid profile in IBD patients with active
disease might be of clinical importance in terms of statin
treatment of IBD patients with atherogenic risk factors
and continuous inflammation or frequent flares. Unfor-
tunately, no discriminant biomarkers could be associated
with the differentiation of CD and UC, nor could actual
response biomarkers be identified, although IBD patients
not responding to IFX were characterised as a poten-
tially distinct group. However, with the increasing num-
ber of biological treatment options (e.g. TNF-α
inhibitors and integrin antagonists) [51] and novel small
molecules (e.g. Janus kinase inhibitors) [52], it will be-
come imperative to develop predictive response bio-
markers in order establish relational individualised
medical treatment regimes.
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